Redeye continues to see potential for stellar growth ahead for Genovis following its Q2 2023 report, which showcased 40% sales growth coupled with 20% EBIT margins. In this report we discuss the report, recent developments and slightly upwards adjust our base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Genovis Q2 2023 - Strong growth and expanding EBIT margin

© Modular Finance, source Nordic Press Releases